Jounce Therapuetics registers for a 2017 IPO
At least one biotech has lined up for a shot at the public markets in 2017. Cancer immunotherapy company Jounce Therapeutics filed with the SEC on Friday, outlining plans for an IPO that could be worth up to $75 million.